Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Chuaqui

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2015
Identification of azabenzimidazoles as potent JAK1 selective inhibitorsMelissa M Vasbinder, Marat Alimzhanov, Martin Augustin, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|June 12, 2022
Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disordersJohn Malona, Claudio Chuaqui, Boris M Seletsky, et al.
Journal of Medicinal Chemistry|June 2, 2018
Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase InhibitorsNeil P Grimster, Erica Anderson, Marat Alimzhanov, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletionsLinda Julian, Lisa Crozier, Devon Lukow, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2015
Identification of azabenzimidazoles as potent JAK1 selective inhibitorsMelissa M Vasbinder, Marat Alimzhanov, Martin Augustin, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|June 12, 2022
Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disordersJohn Malona, Claudio Chuaqui, Boris M Seletsky, et al.
Journal of Medicinal Chemistry|June 2, 2018
Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase InhibitorsNeil P Grimster, Erica Anderson, Marat Alimzhanov, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletionsLinda Julian, Lisa Crozier, Devon Lukow, et al.
Pageof 3